The tooth fairy might leave you some spare change, but Nobel Biocare can fix you up with restorative dental implants, crowns, or bridgework when your natural teeth fail you. The company also makes dental prosthetics (dentures) and has products to plug up any small gaps between teeth for purely aesthetic reasons. Its high-tech offerings include biomaterial implants, diagnostic imaging systems, and guided surgery systems. Its brands include Brånemark, NobelActive, NobelDirect, and NobelProcera. Based in Switzerland, the company has a direct sales presence in some 35 countries and also sells through distributors, giving its products a global reach to about 60 countries.
Nobel Biocare has also been working to expand its geographic reach by establishing new subsidiaries and partnerships in international markets. It formed several preferred partnership agreements in 2010 to expand its marketing and distribution networks in Europe and Asia. In addition to its sales network, Nobel Biocare has production facilities in Canada, Israel, Japan, Sweden, and the US.
The company has been working to broaden its product lines through acquisitions. In 2009 the company bought BioCad Medical, a computer-aided software developer, for about $36 million, and it purchased Medicim, a Belgian imaging firm that bolstered Nobel Biocare's digital dentistry business.
In addition to acquisitions, the firm expands its dental device offerings through research and development efforts. The company rebranded its Procera line as NobelProcera to streamline its branding practices in 2009; Nobel Biocare then spent much of 2010 rolling out a new line of NobelProcera individualized prosthetics that were directly tied to the technology acquisitions made the previous year. In addition, the company launched the NobelActive line of implants in 2008 to supplement the existing NobelReplace offerings, and it introduced a related line of overdenture implants under the Replace Select TC brand in 2010.
While the focus on product development and marketing infrastructures, as well as manufacturing technology upgrades, failed to create positive financial growth in 2010, the company is counting on its investments in these areas to create strong returns in subsequent years. Economic conditions have also played a factor in Nobel Biocare's operations, as consumers have decreased spending on elective procedures, but the firm hopes improving conditions will help to refresh its sales.
In 2011 the company appointed a new CEO, Richard Laube, a former Nestlé executive. Laube replaced former CEO Domenico Scala. – less
3 salaries reported
$106,944 per year